![lab-217043_1280-3358091](<a href="https://rmarketingdigital.com/en/wiki/https/" target="_blank" data-wpel-link="internal">https</a>://rmarketingdigital.com/wp-content/uploads/2021/04/lab-217043_1280-3358091.jpg)
<>
As soon as the results are obtained, Oryzon can become one of the positive surprises for next year in the Spanish equity market. Because you still present room for improvement in your trading accounts that is worthy of value by financial analysts. Where it has a potential for revaluation that can be very powerful if the expectations created in the stock market are met, as the main characteristic in this class of securities that are listed on the national continuous market.
This listed company was founded in 2000 in Barcelona, and Oryzon is a biopharmaceutical company European leading clinical stage in epigenetics. Where it stands out for having one of the strongest portfolios in the sector. Even though it is an initiative to make our savings profitable, it is driven by strong impulses, in one sense or another. Where you can still earn a 20% of profitability in a very short space of time than leaving the same or even more percentage in this period of permanence. It is reserved for small and medium investors who know how to operate with these securities and who at the same time present some learning in their movements in the equity markets.
While on the other hand, it is immersed in a sector, that of biopharmaceutical companies, which is characterized by its high volatility in the conformation of its prices. As soon as you can raise a 5%, the next day the same amount is left in the percentage. They are values that are very conducive to the operation of Commerce dado que sus márgenes son muy amplios frente a cualquier tipo de strategy de inversión. Para que de esta dinámica se pueda rentabilizar el dinero de una forma más extensa que a través de otros valores que cotizan en el índice selectivo de renta variable española, el Ibex 35.
Oryzon trades close to 2 euros
At this time, the company's shares are trading at just over two euros and after an annual revaluation that is defined in 11%. Even though with many differences in each of the months since it is a listed company that is moved more by expectations than by realities. As one of its main differences with respect to the first final values that are integrated into the Ibex 35. Where any error can lead to appreciations around the 5% or even higher percentages, as has happened in recent years. years.
Sea cual sea el caso, es un valor de mercado que tiene su peso target establecido en a little more than 3 euros per share. In other words, it currently has a potential revaluation of almost 15%. From this point of view, there is no doubt that it is a national equity initiative that invites people to take positions to make savings profitable in a short period of time. Despite the many ups and downs he has been suffering in the financial markets.
Nature of the company
This company belongs to a very disruptive sector and little explored by our equities. If not, on the contrary, it is in a segment that is conducive to performing operations of speculative character to obtain capital to settle movements in the stock market. Because indeed, and so that you have a little clearer ideas from now on, it is convenient that you know what is the professional activity that this listed company has been developing. So that you can make a more informed choice and thus avoid falling into some kind of mistakes that can cost your personal interests dearly. And that is, after all, one of his priority goals now.
Well, Oryzon Genomics, SA, a biopharmaceutical company in clinical stage focused on epigenetics for the development of therapies in diseases with important unresolved medical needs. It is, in short, a very new sector and one of which there are very few representatives in the national equity markets. Even from secondary markets such as Alternative stock market (MAB) that are characterized by their high liquidity. Where you may have certain problems adjusting the entry and exit prices in the security.
Value features
A listed company, as in this case, stands out especially because its contracting volume is very low, given that move very few titles every day and that in a way it can harm you in the movements that you are going to perform from now on. Among other reasons due to the fact that you cannot always make purchases at the time you want. As one of the hallmarks in this class of recently-appearing proposals that are not the most desired titles to generate a stable savings bag in the medium and long term. And in some cases, not even in the short term due to the risks that can be taken on in this type of stock market operation.
While on the other hand, it cannot be forgotten that this specific value is very prone to carry out operations in a very few days, even within the same trading session. To get capital gains, the faster the better for your investment strategies. Surely, not hold office for many months or even years. For this you have other values that are more advisable from any investment perspective. For example, those represented by members of the selective national equity index, the Ibex 35. With options such as Mapfre, Endesa, BBVA or ACS.
Risks in operations
As we have spoken before, one of the dangers when taking positions in this special security is the risk that this type of operations implies. In the sense that you can stay hooked or on the contrary, that you directly lose many euros along the way. Because one of the keys to staying in value is knowing how to leave at the right time and without lengthening positions under any circumstances. In fact, you have to be very aware of its evolution in the equity markets before what may happen in the following trading sessions.
On the other hand, it should also be noted that this value is rarely part of the investment portfolios developed by managers, both nationally and outside of our borders. Being somewhat unprotected from the recommendations of the different financial intermediaries. In other words, you will have more problems to develop any investment strategy and that can cause you some other inconvenience in the operations. From the approach that decided to make the capital earmarked for these movements in the stock market profitable.
Through operations that provide little security, as occurs with the securities that are part of the Ibex 35. From this point of view, one must act with much more caution than in these so as not to have negative surprises that could make us reduce the balance of your savings account. Only from more or less reasonable margins for your interests in the financial markets. Because at the end of the day what it is about is to make money profitable in the absence of alternatives in fixed income. Where interests barely exceed 0.3%, as in the case of fixed-term bank deposits. Therefore, a lot of diligence when opening positions because the risk is always latent at any time. More than you can believe from the beginning and that can not lead you to meet the objectives.
Increase your income with a 42%
Revenues at the end of the third quarter of 2019 of this company amounted to a total of 7.4 million euros, 42.3% more than in the third quarter of 2018. The company has recognized income from work carried out for its own fixed assets. of 7.4 million euros. In the investments in R&D is 8.2 million euros, of which 7.4 million euros correspond to development and 0.8 million euros to research, which have been taken directly to expenses for the period, which represents an increase of 51, 9% in investment capacity compared to the third quarter of 2018. decided to capitalize on the capital allocated to these movements in the stock market.
The net result of its accounting balance is 2.7 million euros of loss, according to the specificity of the biotechnology business model, in the development stage in which the company is, with a long maturity period of its products term, and without recurrences. from an income perspective. Where at the end of the third quarter the cash and financial investments available amounted to 39.1 million euros. While, on the other hand, it has carried out a capital increase equal to 20.0 million euros, attracting the interest of international investors.
